IMMUNOLOGY

Probing Molecular
Mechanisms of
Viral-Host Interactions

Holly Ramage, PhD, assistant professor of
microbiology and immunology, is taking on some of
the world’s most prevalent infectious diseases. She
seeks to understand the molecular mechanisms of
viral-host interactions in the flaviviruses—including
dengue, Zika and West Nile virus—that are endemic
in many areas of the world.
“Increasing evidence indicates that many viruses,
including flaviviruses, have evolved mechanisms to
manipulate cellular machinery in order to promote
infection,” Dr. Ramage says. “My lab examines
the physical interactions that occur between
flavivirus and host-cell proteins. We use powerful
proteomics and genomics techniques—including
siRNA knockdowns, CRISPR knockouts and
mutagenesis strategies—to identify the changes
in cellular proteins that allow viral infection and
permit viruses to evade the immune system.”
Currently, there are no specific antiviral treatments
for any of the flaviviruses that infect hundreds of
millions of people each year. But scientists do know
that in order to replicate, flavivirus proteins must
physically engage with—and subvert—a host cell’s
antiviral capacities. For that reason, Dr. Ramage
has undertaken an NIH-funded study that aims to
identify the physical interactions that occur during
West Nile virus infection and that enable the virus
to evade the immune system. In previous work, she
pinpointed the cellular proteins that are targeted
by West Nile virus in the infection process—and
identified that eight of those proteins are also
involved in the infection processes used by dengue
and Zika viruses. The current study focuses the role
that two of those proteins play in antiviral signaling.
“There is strong reason to believe that multiple
flaviviruses have a shared mechanism for
evading the immune system,” Dr. Ramage
notes. “Therefore, this work and our follow-up
studies may inform new targets for therapeutic
intervention against a number of these infections.”
Over the past year, Dr. Ramage has also been
applying her lab’s expertise and approaches to
identify drugs that have the potential to stop the
SARS-CoV-2 virus in its tracks. The project’s focus
is the sigma-1 receptor protein, which plays a

10

Thomas Jefferson University | Jefferson.edu/Research

Zika virus. Atomic level
structure, determined
by Cryo-EM.

multifunctional role in scaffolding intracellular
membranes and which may be key to how
viruses move into and through a cell. This study
is exploring the potential to use a specific smallmolecule compound that targets the sigma-1
receptor—a compound originally designed to treat
prostate cancer—to stop the coronavirus from
entering and replicating within cells.
“Coronaviruses are entirely dependent on the host’s
cellular machinery to replicate,” Dr. Ramage notes.
“We hypothesize that the sigma-1 receptor could
be an important cellular factor that is required
by SARS-CoV-2 to replicate and produce new
infectious viral particles.”
Specifically, this study focuses on the ability of
sigma-1-targeted compounds to disrupt two
proteins crucial to infection and replication: the
virus’s spike protein and the host cellular protein
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TMPRSS2—elevated levels of which dramatically
increase susceptibility to SARS-CoV-2 infection
in certain cell types.
“If our central hypothesis is accurate, these sigma-1targeted agents will block the maturation of the spike
protein and suppress cellular TMPRSS2 expression,”
Dr. Ramage explains, “effectively inhibiting infection.”
Moreover, they could form the basis for treatments
of a range of coronaviruses. 
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